EP2197434A4 - Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique - Google Patents

Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Info

Publication number
EP2197434A4
EP2197434A4 EP08831905A EP08831905A EP2197434A4 EP 2197434 A4 EP2197434 A4 EP 2197434A4 EP 08831905 A EP08831905 A EP 08831905A EP 08831905 A EP08831905 A EP 08831905A EP 2197434 A4 EP2197434 A4 EP 2197434A4
Authority
EP
European Patent Office
Prior art keywords
resveratrol
activity
gene product
containing compositions
product concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08831905A
Other languages
German (de)
English (en)
Other versions
EP2197434A1 (fr
Inventor
William F Sardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resveratrol Partners LLC
Original Assignee
Resveratrol Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resveratrol Partners LLC filed Critical Resveratrol Partners LLC
Publication of EP2197434A1 publication Critical patent/EP2197434A1/fr
Publication of EP2197434A4 publication Critical patent/EP2197434A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08831905A 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique Withdrawn EP2197434A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US97381707P 2007-09-20 2007-09-20
US2323408P 2008-01-24 2008-01-24
US2323008P 2008-01-24 2008-01-24
US2322708P 2008-01-24 2008-01-24
US4875608P 2008-04-29 2008-04-29
US4876908P 2008-04-29 2008-04-29
US4874708P 2008-04-29 2008-04-29
PCT/US2008/076707 WO2009039195A1 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Publications (2)

Publication Number Publication Date
EP2197434A1 EP2197434A1 (fr) 2010-06-23
EP2197434A4 true EP2197434A4 (fr) 2011-08-10

Family

ID=40468316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08831905A Withdrawn EP2197434A4 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Country Status (4)

Country Link
EP (1) EP2197434A4 (fr)
JP (2) JP2010540444A (fr)
CA (1) CA2699908C (fr)
WO (1) WO2009039195A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263051B2 (en) * 2007-08-09 2012-09-11 Hallstar Innovations Corp. Photostabilization of resveratrol with alkoxycrylene compounds
JP5979810B2 (ja) * 2009-10-09 2016-08-31 株式会社山田養蜂場本社 抗老化剤
EP2525791A2 (fr) * 2010-01-21 2012-11-28 INSERM - Institut National de la Santé et de la Recherche Médicale Composition particuliere pour son application comme medicament
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP5608629B2 (ja) * 2011-11-28 2014-10-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
KR20150043566A (ko) * 2012-09-12 2015-04-22 버그 엘엘씨 심장독성 약제의 동정에 마커를 사용하는 용도
CN102908338B (zh) * 2012-11-20 2014-05-14 晨光生物科技集团天津有限公司 白藜芦醇微胶囊的制备方法
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
JP5933633B2 (ja) * 2014-06-18 2016-06-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
PL3237295T3 (pl) * 2014-12-23 2023-06-26 Intelligent Packaging Pty Ltd. Sposób wytwarzania pojemnika na towar konsumpcyjny, powlekanego warstwą zawierającą resweratrol
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
JP6272946B2 (ja) * 2016-05-20 2018-01-31 株式会社山田養蜂場本社 抗老化剤
KR102619197B1 (ko) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
AU2018250727A1 (en) 2017-04-11 2019-10-31 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family
EP3695012B1 (fr) 2017-10-11 2023-03-08 Regeneron Pharmaceuticals, Inc. Inhibition de hsd17b13 dans le traitement de la maladie hépatique chez des patients exprimant la variation pnpla3 i148m
JP6411624B2 (ja) * 2017-12-26 2018-10-24 株式会社山田養蜂場本社 抗老化剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298876A (ja) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk サーチュインの活性化剤を含む各種眼疾患治療用組成物
US7582674B2 (en) * 2003-05-27 2009-09-01 Dsm Ip Assets B.V. Nutraceutical compositions and use thereof
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
CN1956733B (zh) * 2004-04-07 2012-10-10 白藜芦醇合伙人有限责任公司 营养补充剂及其加工方法
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007019417A1 (fr) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Dérivés d’oxazolopyridine comme modulateurs du sirtuin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009039195A1 *

Also Published As

Publication number Publication date
EP2197434A1 (fr) 2010-06-23
CA2699908C (fr) 2012-09-11
JP2014058574A (ja) 2014-04-03
WO2009039195A1 (fr) 2009-03-26
CA2699908A1 (fr) 2009-03-26
JP2010540444A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
EP2197434A4 (fr) Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique
HK1245088A1 (zh) 促神經營養蛋白的活性的調節
GB2460957B (en) Desktop sterilizer for books
LT2334705T (lt) Biologiniai produktai
HK1163689A1 (en) Methods and compositions for modulating ire1, src, and abl activity ire1src abl
GB0614780D0 (en) Biological products
GB0612928D0 (en) Biological products
GB0620729D0 (en) Biological products
PL2303891T3 (pl) Pirazolo-chinazoliny jako modulatory aktywności kinaz białkowych
EP2268825A4 (fr) Microorganismes immobilisés, tolérants à un produit
PL2222311T3 (pl) Ciekły produkt zawierający nukleotydy/nukleozydy
PL2271660T3 (pl) Stabilizowane ciekłe kompozycje enzymów
GB201106793D0 (en) Droplet-based System
IL192925A0 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
EP2166093A4 (fr) Composition pharmaceutique pour thérapie par remplacement enzymatique
GB0807413D0 (en) Biological products
ZA200908556B (en) Mixed product
EP2015782A4 (fr) Compositions et procédés permettant de moduler l'expression des gènes
EP2196525A4 (fr) Composition de parfum de type jasminum sambac
EP2271739A4 (fr) Produit pour culture cellulaire
GB0702681D0 (en) DNA-based biosensors
GB0703971D0 (en) Product carrier
ITMI20071255A1 (it) Contenitore per prodotti versabili
GB0725268D0 (en) Biological products
GB0718833D0 (en) Biological products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110708

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7056 20060101ALI20110704BHEP

Ipc: A61K 31/05 20060101AFI20110704BHEP

17Q First examination report despatched

Effective date: 20130715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150401